Pharmacy Disclosure Log 2025

  1. Asthma Response 1003
  2. Asthma Response 1003 Attachment
  3. Atopic Dermatitis Response 981
  4. Biologics Rheumatology Response 1057
  5. Biologics - Dermatology Response 1046
  6. Biologic Medicines in Gastroenterology Response 847
  7. Biologics Gastro Response 1128
  8. Biologics Rheumatology Response 762
  9. Blood Cultures Response 940
  10. Bruxism Data Response 1134
  11. Curosurf and Peyona Response 1110
  12. Dermatology and Respiratory Medicine Response 977
  13. Dermatology Response 771
  14. Diffuse Large B Cell Lymphoma Response 827
  15. Endometrial Cancer Response 923
  16. Eosinophilic Oesophagitis (EoE) Response 972
  17. Elastomeric Infusion Devices Response 1031
  18. Fibrinogen Concentrate, Prothrombin Complex Concentrate, DOAC Antidote, and Blood Products Response 772
  19. Fibrinogen Concentrate, Prothrombin Complex Concentrate, DOAC Antidote, and blood Products Response 772 Attachment
  20. Formularies and Committees Response 941
  21. Friedreich Ataxia Response 921
  22. Gastroenterology Response 1156
  23. Giant Cell Arteritis Response 1083
  24. Human Albumin Response 826
  25. Immunoglobulin Treatment Response 932
  26. Intra-Vitreal Injections Implants Response 810
  27. Intra-vitreal treatments Response 870
  28. Intra-Vitreal Injections or Implants Response 1066
  29. Intra-Vitreal Treatments Response 1145
  30. Lung Cancer Response 1148
  31. Lung Cancer Response 864
  32. Lung Cancer Response 864 Attachment
  33. Medication errors Rocuronium Response 918
  34. Melanoma Response 901
  35. Migraine Response 856
  36. Migraine Response 1138
  37. Multiple Myeloma Response 1015
  38. Multiple Sclerosis Response 1079
  39. Multiple Sclerosis Response 1079 - Attachment
  40. New Biologic and Targeted Medications Response 867
  41. Non-Medical uses of Blood Response 802
  42. NHS Pharmacy Aseptic Services Response 803
  43. Oncology Breast Cancer Response 1118
  44. Oncology Response 1146
  45. Oncology Breast Cancer Response 857
  46. Oncology Response 928
  47. Orthopaedic Antibiotic Guidelines for Open Fractures, Closed Trauma, and Elective Surgery Response 1155
  48. Orthopaedic Antibiotic Guidelines for Open Fractures, Closed Trauma, and Elective Surgery Response 1155 - Attachment
  49. Ovarian Cancer Response 944
  50. Pancreatic Enzyme Replacement Therapy (PERT) Response 1114
  51. Patients treated with Ruxolitinib Response 933
  52. Patients treated with Ruxolitinib Response 933 Attachment
  53. Prescription CBPMs Response 998
  54. Prescription CBPMs Response 998 - Attachment
  55. Primary Diagnosis of GCA Response 784
  56. Prostate Cancer Patient Response 984
  57. Renal Cell Carcinoma Response 871
  58. Renal Cell Carcinoma Response 871 Attachment
  59. Social Prescribing Response 1021
  60. Sodium Chloride and Levofloxacin in Ophthalmology Response 994
  61. Spinal Muscular Atrophy Response 794
  62. Spinal Muscular Atrophy Response 1078
  63. Spinal Muscular Atrophy Response 1078 - Attachment
  64. Treatment of Insomnia Response 1109
  65. Treatment of Breast Cancer Response 1112
  66. Treatment of Breast Cancer Response 1112 - Attachment
  67. Trust Processes to Reduce Medication Waste Response 885
  68. Urothelial Cancer Response 930
  69. Wound Formulary Response 860